multi-strain probiotic capsules Search Results


multi strain probiotic capsule  (ATCC)
95
ATCC multi strain probiotic capsule
Quantity of samples collected during the PICO study.
Multi Strain Probiotic Capsule, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi-strain+probiotic+capsules/Lactobacillus+acidophilus%2C+NCFM/pmc06161886-31-22-29
Average 95 stars, based on 1 article reviews
multi strain probiotic capsule - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
commercial multi-strain probiotic  (Lallemand inc)
90
Lallemand inc commercial multi-strain probiotic
Quantity of samples collected during the PICO study.
Commercial Multi Strain Probiotic, supplied by Lallemand inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi-strain+probiotic+capsules/probiotic+strains/pm37019866-34-4-12
Average 90 stars, based on 1 article reviews
commercial multi-strain probiotic - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Quantity of samples collected during the PICO study.

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: Quantity of samples collected during the PICO study.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques:

The Shannon diversity index, which is a heterogeneity measure that combines richness and evenness components of microbial diversity does not significantly differ when subjects take probiotics.

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: The Shannon diversity index, which is a heterogeneity measure that combines richness and evenness components of microbial diversity does not significantly differ when subjects take probiotics.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques: Probiotics

(A) Subjects in the probiotic group had a significantly lower abundance of the bacterial family Verrucomicrobiaceae at week 8 than placebo treated subjects; (B) Members of the bacterial genus Bacteroides were significantly reduced in abundance between weeks 0 to 4 in probiotic treated subjects; (C) Ruminococcus (family Lachnospiraceae) tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group; * 0.05 < p < 0.1 and ** p ≤ 0.05.

Journal: PLoS ONE

Article Title: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

doi: 10.1371/journal.pone.0204253

Figure Lengend Snippet: (A) Subjects in the probiotic group had a significantly lower abundance of the bacterial family Verrucomicrobiaceae at week 8 than placebo treated subjects; (B) Members of the bacterial genus Bacteroides were significantly reduced in abundance between weeks 0 to 4 in probiotic treated subjects; (C) Ruminococcus (family Lachnospiraceae) tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group; * 0.05 < p < 0.1 and ** p ≤ 0.05.

Article Snippet: After the enrollment period, 33 subjects experiencing a first episode of mild to moderate CDI were randomly assigned an oral placebo or multi-strain probiotic capsule ( Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10 10 CFU/capsule daily for four weeks (week 0 to week 4).

Techniques: